文献速递造血干细胞移植与细胞治疗

基于HLA-DPB1差异的生物学模型预测无关移植临床结局

Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation.
PubMed 文献 · Blood Adv · 2021-01-01

该研究在909对供受者中分析三种生物学模型(TCE、DPB1细胞表面表达、PIRCHE)与经典等位基因错配对无关造血干细胞移植后急性GVHD及生存的预测价值。结果显示两个DPB1等位基因全合仍是预防急性GVHD的最佳选择;单错配时,受者低表达等位基因错配、允许性TCE3/4错配和/或无针对受者PIRCHE II潜力者急性GVHD风险最低;双错配时同样适用允许性TCE3/4错配和无PIRCHE II的考虑。联合生物学模型可定义最有利的DPB1组合以优化供者选择。

要点

  • 双DPB1等位基因全合是预防急性GVHD的最佳选择
  • 单错配时优选受者低表达等位基因错配、允许性TCE3/4、无PIRCHE II
  • 联合三种生物学模型可定义最有利的DPB1组合

核心结论

  • 两个DPB1等位基因全合仍是预防急性GVHD的最佳选择。
  • 单DPB1错配时,受者低表达等位基因错配、允许性TCE3/4错配和/或无针对受者PIRCHE II潜力者急性GVHD风险最低。
  • 双DPB1错配时,允许性TCE3/4错配和无PIRCHE II同样适用。
  • 联合生物学模型可定义最有利的DPB1组合以优化供者选择。

研究设计与样本

  • 在909对受者/供者中分析三种生物学模型与经典等位基因错配的比较。
  • 三种模型为:基于DPB1免疫原性的T细胞表位(TCE)、基于3'非翻译区单核苷酸多态性的DPB1分子细胞表面表达、基于错配HLA来源同种异体肽提呈的PIRCHE模型。

主要发现

  • 两个DPB1等位基因全合是预防急性GVHD的最佳选择。
  • 单DPB1错配时,受者低表达等位基因错配者急性GVHD风险最低,其次为允许性TCE3/4错配和/或无针对受者PIRCHE II潜力。
  • 双DPB1错配时,允许性TCE3/4错配和无PIRCHE II同样适用。
  • 联合生物学模型可定义最有利的DPB1组合。

临床怎么用

  • 在无关HSCT供者选择中,可结合TCE、DPB1表达和PIRCHE II模型优化DPB1错配组合。
  • 优先选择两个DPB1等位基因全合的供者以预防急性GVHD。
  • 无法全合时,单错配优先选择受者低表达等位基因错配、允许性TCE3/4错配和/或无针对受者PIRCHE II潜力的供者。
  • 双错配时优先考虑允许性TCE3/4错配和无PIRCHE II的供者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HLA compatibility is a key factor for survival after unrelated hematopoietic stem cell transplantation (HSCT). HLA-A, -B, -C, -DRB1, and -DQB1 are usually matched between donor and recipient. By contrast, HLA-DPB1 mismatches are frequent, although it is feasible to optimize donor selection and DPB1 matching with prospective typing. Because classical DPB1 allele mismatches are often unavoidable, however, several biological models have been developed to predict the optimal DPB1 mismatch combination for less graft-versus-host disease (GVHD) and better overall survival. In 909 recipient/donor pairs, we analyzed the role of 3 biological models: T-cell epitopes (TCEs) based on the immunogenicity of DPB1, cell surface expression of DPB1 molecules based on a single-nucleotide polymorphism located in the 3' untranslated region, and the Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) model based on the presentation of allogeneic peptides derived from mismatched HLA, compared with the classical allele mismatch. Matching for both DPB1 alleles remains the best option to prevent acute GVHD. In the situation of one DPB1 allele mismatch, the donor associated with the lowest acute GVHD risks is mismatched for an allele with a low expression profile in the recipient, followed by a permissive TCE3/4 mismatch and/or the absence of PIRCHE II potential against the recipient. In the context of 2 DPB1 mismatches, the same considerations apply for a permissive TCE3/4 mismatch and no PIRCHE II. By combining the biological models, the most favorable DPB1 constellation can be defined. This approach will help optimize donor selection and improve post-HSCT complications and patient prognosis.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Buhler S, Baldomero H, Ferrari-Lacraz S, et al. Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation. Blood Adv. 2021. PMID: 34448833. doi:10.1182/bloodadvances.2020003998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。